【US stock movement】Grail surged on October 5: FDA support + Galleri early screening

Grail October 5th Surge Analysis

Keywords: FDA support, Galleri early cancer screening

1. On September 23, the FDA Medical Device Advisory Committee held three votes on the Galleri multi-cancer early detection blood test: safety was unanimously supported by all 10 committee members, benefit outweighs risk received 7 votes in favor and 2 against, and effectiveness received 6 votes in favor and 4 against, providing regulatory progress for subsequent PMA review.

2. On September 23, GRAIL stated that Galleri, targeting people aged 50 and above, can detect multiple types of cancer. The company explained that the test is designed to detect cancers for which there are currently no recommended screening methods, and related regulatory review progress has become a core recent event driver.

3. As of June 30, the company’s Galleri test volume in the first half of the year increased by 42% year-on-year to over 117,000 tests, and cash plus short-term marketable securities totaled $861.6 million. As of June 30, the company still maintains a commercialized Galleri blood testing business, providing funding support for business expansion.

(Disclaimer: This content is summarized and generated by AI technology based on publicly available information and is for reference only. It does not constitute investment advice.)